Agios Pharmaceuticals, Inc. (0HB0.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
88 Sidney Street
Cambridge, MA 02139-4169
United States of America (the)
Phone
617 649 8600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
486
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| Brian Goff | Chief Executive Officer & Director | 1.45M | 1969 |
| Tak Wah Mak FRSC | Co-Founder | 50,000 | 1946 |
| Craig Thompson | Co-Founder | 50,000 | 1953 |
| Lewis Clayton Cantley | Co-Founder | 50,000 | 1949 |
| Shin-San Su | Co-Founder | 50,000 | 1956 |
| James William Burns | Chief Legal Officer | 780,510 | 1978 |
| Cecilia Jones | Chief Financial Officer | 791,835 | 1975 |
| Tsveta Milanova | Chief Commercial Officer | 836,643 | 1978 |
| Sarah Gheuens | Chief Medical Officer and Head of Research & Development | 887,232 | 1980 |
| Krishnan Viswanadhan | Chief Strategy & Operations Officer | 931,509 | 1979 |
| T. J. Washburn | Vice President, Controller & Principal Accounting Officer | 0 | 1982 |
| Clive Patience | Chief Technical Operations Officer | 0 | 1964 |
| Steven Vickers | Vice President of Sales | 0 | N/A |
Agios Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of treatments within cellular metabolism and associated biological domains. Its lead product, PYRUKYND (mitapivat), serves as an activator for both healthy and various mutated forms of the pyruvate kinase (PK) enzyme, targeting the management of hemolytic anemias. Additionally, AG-946, an investigational compound, is currently undergoing Phase I clinical evaluation for hemolytic anemias and other conditions. Established in 2007, Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.